Potential Therapeutic Targets of Inflammation of Alzheimer’s Disease

The activation of inflammasome is related to the occurrence of amyloid and inflammatory mediators. Therefore, the resistance to inflammation by anti-inflammasome can delay the development of AD (Alzheimer’s disease) and is a promising treatment strategy for AD. Semi-quantitative RT-PCR and Western blot were preliminarily used to screen the inflammation-related genes in primary microglia and macrophage stimulated and induced by Aβ1-42, including regulatory changes in immune inflammatory pathways, extracellular receptors closely related to inflammasome and nucleic acid recognition regulatory pathways. These inflammation-related data provide important basis for targeted therapy of inflammasome and delay the onset and progression of AD.